| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db889de540f1640afc29772109da9a27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ee06fc836fcae3e47f2a68c86f4ee66 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10371
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10322 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2474
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2010-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ced241b9fb5f4d289dd9368e796e82c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b2598cbc4535c4c8f867c865ba57d5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8b7e6cf57e547202638d21f73503803 |
| publicationDate |
2011-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2010244348-A1 |
| titleOfInvention |
Oncolytic adenoviruses for treating cancer |
| abstract |
The invention relates to an oncolytic adenovirus that comprises a sequence that encodes a hyaluronidase enzyme inserted in the genome thereof. This adenovirus is distributed more efficiently through the mass of the tumour and consequently the oncolytic effect is enhanced. Endovenous injection of the oncolytic adenovirus of the invention gives rise to regressions in tumour volume. Therefore, the oncolytic adenovirus of the present invention can be used to treat cancer or a pre-malignant stage thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11439678-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11000559-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10849945-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10548929-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2016256582-B2 |
| priorityDate |
2009-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |